Fangzhou and Tencent Health: Revolutionizing Chronic Disease Management with AI

(SeaPRwire) –   By: Logan Pierce, Independent Business Writer

Fangzhou Inc., a leading provider of AI-driven Internet healthcare solutions, recently showcased its “AI + Chronic Disease Services” digital solution at the 2026 Tencent Cloud AI Industry Applications Summit in Beijing. The solution, developed in collaboration with Tencent Health, aims to transform chronic disease management by integrating AI into the “AI + H2H (Hospital-to-Home)” smart healthcare ecosystem.

Fangzhou’s AI + Chronic Disease Services solution is built on its proprietary XingShi Large Language Model (XS LLM) and is designed to enhance care delivery, improve patient outcomes, and expand access to professional healthcare services. The solution focuses on supporting both patients and physicians across the chronic disease management journey, providing personalized health management recommendations, risk monitoring, and behavioral interventions for patients, and reducing administrative workloads and streamlining routine tasks for physicians.

The summit also highlighted the ongoing collaboration between Fangzhou and Tencent Health. Since expanding their strategic partnership in November 2025, the two companies have worked together to combine Fangzhou’s healthcare expertise and chronic disease management capabilities with Tencent Health’s technology infrastructure, supporting the development and deployment of AI applications across a broad range of healthcare use cases.

Tencent Health’s technology platform provides Fangzhou with access to scalable computing resources and end-to-end model development tools that support the continuous optimization of its AI capabilities. The solution also utilizes Tencent Health’s vector database technology, enabling rapid retrieval from large-scale medical knowledge repositories and improving the accuracy and reliability of AI-generated content.

Fangzhou will continue to prioritize technological innovation and ecosystem collaboration as key pillars of its long-term growth strategy. By working closely with Tencent Health and other industry partners, the company aims to further expand the reach of AI-powered chronic disease services, helping deliver more efficient, personalized, and accessible healthcare support to patients while contributing to the digital transformation of China’s healthcare sector.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians as of December 31, 2025. The company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.